Alzamend Neuro (ALZN) News Today $0.76 -0.03 (-3.68%) Closing price 04:00 PM EasternExtended Trading$0.78 +0.02 (+1.97%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comAlzamend Neuro CFO David Katzoff acquires $5,048 in common stockMarch 26, 2025 | investing.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General HospitalMarch 25, 2025 | globenewswire.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General HospitalMarch 18, 2025 | globenewswire.comAlzamend Neuro files to sell 75.775M shares of common stock for holdersMarch 14, 2025 | markets.businessinsider.comAlzamend Neuro announces initiation of Phase II trial of AL001March 12, 2025 | markets.businessinsider.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General HospitalMarch 11, 2025 | globenewswire.comAlzamend Neuro Announces Bylaws Amendment and New Stock SeriesMarch 5, 2025 | investing.comAlzamend Neuro announces initiation date of Phase II trial of AL001March 4, 2025 | markets.businessinsider.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General HospitalMarch 4, 2025 | globenewswire.comAlzamend Neuro (ALZN) Gets a Hold from Maxim GroupFebruary 26, 2025 | markets.businessinsider.comAlzamend Neuro announces initiation data of Phase II trial of AL001February 26, 2025 | markets.businessinsider.comAlzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General HospitalFebruary 25, 2025 | globenewswire.comAlzamend Neuro announces completion of head coil by Tesla Dynamic CoilsFebruary 19, 2025 | markets.businessinsider.comAlzamend Neuro to Present at the Sequire Investor SummitJanuary 15, 2025 | stockhouse.comAlzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpoDecember 19, 2024 | finance.yahoo.comAlzamend Neuro says net cash gained by financing activity $8.3MDecember 12, 2024 | markets.businessinsider.comEXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug PotentialNovember 19, 2024 | finance.yahoo.comAlzamend Neuro regains Nasdaq compliance with equity ruleOctober 17, 2024 | uk.investing.comAlzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer'sOctober 16, 2024 | stockhouse.comEXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer'sOctober 16, 2024 | msn.comAlzamend Neuro Regains Compliance with Nasdaq Listing StandardsOctober 15, 2024 | finance.yahoo.comAlzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare ConferenceOctober 10, 2024 | finance.yahoo.comAlzamend Neuro Issues Letter to StockholdersAugust 26, 2024 | finance.yahoo.comAlzamend Neuro Shares Rise on Partnership for PTSD Treatment Mid-Stage StudyAugust 20, 2024 | marketwatch.comAlzamend Neuro (NASDAQ:ALZN) Stock, Short Interest ReportAugust 20, 2024 | benzinga.comAlzamend Neuro (NASDAQ:ALZN) Stock Quotes, Forecast and News SummaryAugust 20, 2024 | benzinga.comAlzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: DetailsAugust 20, 2024 | msn.comAlzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive DisorderAugust 12, 2024 | theglobeandmail.comAlzamend Neuro partners with Mass General for Phase II trialAugust 8, 2024 | uk.investing.comAlzamend Neuro director buys shares worth $93August 3, 2024 | investing.comAlzamend Neuro regains Nasdaq compliance with bid priceAugust 2, 2024 | investing.comALZN Alzamend Neuro, Inc.July 19, 2024 | seekingalpha.comAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionMay 9, 2024 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred SharesMay 9, 2024 | finance.yahoo.comAlzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares SlideMay 7, 2024 | msn.comAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramMay 7, 2024 | finance.yahoo.comAlzamend Neuro And 2 Other Stocks Under $5 Insiders Are BuyingApril 24, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42April 17, 2024 | msn.comALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024March 26, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50February 24, 2024 | msn.comMaxim gets more bearish on Alzamend Neuro, downgrades sharesFebruary 13, 2024 | realmoney.thestreet.comAlzamend Neuro Risks Nasdaq Delisting Over Price DeficiencyFebruary 3, 2024 | msn.comBuy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market PotentialDecember 19, 2023 | markets.businessinsider.comALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024December 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024December 18, 2023 | msn.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsDecember 11, 2023 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next YearDecember 11, 2023 | finance.yahoo.comAlzamend Neuro Gets FDA Approval for Trial of Depression TreatmentNovember 20, 2023 | marketwatch.comEXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder StudyNovember 20, 2023 | msn.com Remove Ads Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address ALZN Media Mentions By Week ALZN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALZN News Sentiment▼0.290.78▲Average Medical News Sentiment ALZN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALZN Articles This Week▼20▲ALZN Articles Average Week Remove Ads Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Eagle Pharmaceuticals News Today Alterity Therapeutics News Today CalciMedica News Today KALA BIO News Today Cyclo Therapeutics News Today VYNE Therapeutics News Today Clene News Today Tenax Therapeutics News Today Cara Therapeutics News Today Cognition Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALZN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALZN Stock Free ALZN Stock Alerts